Strong sales performance of Cresemba (isavuconazole) in Europe leads to USD 25 million milestone payment to Basilea Page 1

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, September 6, 2024

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with serious bacterial and fungal infections, today announced that sales of its antifungal Cresemba (isavuconazole) by licensing partner Pfizer in Europe have exceeded the threshold triggering a $25 million milestone payment to Basilea.